Liu Fong W, Cripe James, Tewari Krishnansu S
Oncology (Williston Park). 2015 May;29(5):350-60.
Anti-angiogenic agents are an important adjuvant treatment strategy in gynecologic cancer. Bevacizumab was recently approved for use in advanced cervical cancer and platinum-resistant ovarian cancer. The overall survival advantage bevacizumab confers in advanced cervical cancer prompted a paradigm shift in the standard of care for this disease. Because many other therapeutic options are available, and because of the heterogeneity of ovarian malignancies, the best combination of chemotherapeutics and bevacizumab has yet to be determined; studies are on-going. The utility of bevacizumab in uterine cancer has not been consistently demonstrated; current studies are limited to early-phase clinical trials. Other anti-angiogenic agents, including oral therapies for cervical and ovarian cancers, are under investigation; this therapeutic class of drugs appears promising.
抗血管生成药物是妇科癌症的一种重要辅助治疗策略。贝伐单抗最近被批准用于晚期宫颈癌和铂类耐药的卵巢癌。贝伐单抗在晚期宫颈癌中带来的总生存优势促使了该疾病护理标准的范式转变。由于有许多其他治疗选择，且卵巢恶性肿瘤具有异质性，化疗药物与贝伐单抗的最佳组合尚未确定；相关研究正在进行中。贝伐单抗在子宫癌中的效用尚未得到一致证实；目前的研究仅限于早期临床试验。其他抗血管生成药物，包括用于宫颈癌和卵巢癌的口服疗法，正在研究中；这类治疗药物似乎很有前景。
